Medicago, a biopharmaceutical company headquartered in Quebec City, recently announced that they have successfully produced a Virus-Like Particle (VLP) of the coronavirus just 20 days after obtaining the SARS-CoV-2 (virus causing the COVID-19 disease) gene.
Production of the VLP is the first step in developing a vaccine for COVID-19 which will now undergo
preclinical testing for safety and efficacy. Once this is completed, Medicago expects to discuss with the
appropriate Health Agencies to initiate human trials of the vaccine by summer (July/August) 2020.
The Federal Government has announced funding for Medicago, a Quebec City-based company with 20 years of experience in plant-based vaccines and therapeutics, that has identified a viable plant-based vaccine candidate currently at the pre-clinical testing phase. Funding will allow Medicago to rapidly move forward on clinical trials and then quickly shift to scaling up production for pandemic response.